Cat scratch disease (CSD) is a self limited zoonotic disease that presents most commonly as a regional lymphadenopathy. We are reporting a case of a 25-year-old male patient who presented with fever and large right inguinal lymphadenopathy. The diagnosis of cat scratch disease was confirmed based on the characteristic cytopathological features on aspirate smears from the lymph node and the serological titers for Bartonella henselae. This case report emphasizes the importance of combining Bartonella serology, and cytopathology in the diagnostic work-up of febrile lymphadenopathy and suspected CSD since the culture of this organism is arduous.

BACKGROUND. The cytologic differentiation between neoplastic and reactive/reparative processes in the endoscopic ultrasound-guided fine-needle aspirations (EUS-FNA) of the pancreas can be difficult. Malignant transformation of the pancreatic ductal epithelium changes the expression of apomucins. The goal of the current study was to determine an optimal immunohistochemical panel of mucin (MUC) antibodies that would allow the cytomorphologic distinction of pancreatic ductal adenocarcinoma and its differentiation from reactive/reparative processes and inadvertently sampled gastric and duodenal mucosa. METHODS. Pancreatic EUS-FNA specimens performed on 351 patients were reviewed. Expression profiles of MUC1, 2, 5AC, and 6 were examined on 56 cell block sections and 26 follow-up pancreatectomy specimens. RESULTS. MUC1 and 6 expression was found in nonneoplastic pancreatic samples, whereas there was an absence of expression of MUC2 and 5AC. MUC2 was detected in mucosal goblets cells of the duodenum, MUC6 in Brunner glands, and MUC5AC in gastric foveolar cells. MUC5AC expression in differentiating ductal adenocarcinomas from benign conditions demonstrated better operating characteristics than either MUC1 or MUC6. The apomucin expression pattern both in cytology and follow-up surgical pathology specimens was similar. In surgical pathology specimens, the panel of 3 antibodies, MUC1+/MUC2-/MUC5AC+, was noted in 15 of 17 ductal carcinomas (88.2%). In nonneoplastic pancreatic tissue, the expression panel MUC1+/MUC2-/MUC5AC- was observed in 14 of 17 (82.4%) cases. In cytology specimens, the combination of MUC1+/MUC2-/MUC5AC+ was noted in 21 of 30 ductal carcinoma cases (70.0%), 3 of 6 atypical cases (50%), and 1 of 1 suspicious for malignancy cases (100%). The combination MUC1+/MUC2-/MUC5AC+ was not observed in any of the negative for malignancy or reactive cases (0 of 6). CONCLUSIONS. The most optimal panel for the diagnosis of ductal adenocarcinoma in both the EUS-FNA specimens is a panel including MUC1/MUC2/MUC5AC, whereas a panel of all 4 antibodies (MUC1, 2, 5AC, and 6) will in addition aid in differentiating inadvertently sampled normal/reactive duodenal and gastric epithelium from neoplastic pancreatic tissue.

Nódulos de tireoide são achados clínicos comuns e, atualmente, o método diagnóstico de escolha para diferenciar lesões benignas de lesões malignas é a análise citopatológica dos nódulos através de punção aspirativa por agulha fina (PAAF). Estudos prévios já indicaram que os níveis séricos de TSH podem estar associados ao risco de malignidade nodular. O objetivo deste estudo foi avaliar se o TSH sérico é um preditor de malignidade em nódulos de tireoide em pacientes submetidos à PAAF. A amostra contemplou 100 indivíduos puncionados consecutivamente no Centro de Pronto Diagnóstico Ambulatorial, CPDA, HCPA e que apresentavam níveis de TSH dentro da normalidade. Todos os pacientes foram submetidos à PAAF da tireoide com controle ultrassonográfico e tiveram, posteriormente, a análise citopatológica da PAAF e a avaliação histopatológica do bloco celular. A análise estatística baseou-se em dados de frequências e testes não-paramétricos foram utilizados para correlacionar as variáveis. A população de estudo foi composta por 100 pacientes, sendo 89 mulheres e 11 homens. A média de idade foi de 54,1 ± 14,2 anos e o tamanho médio dos nódulos foi de 2.53 ± 1.36 centímetros. Vinte e seis % destes pacientes apresentavam algum tipo de doença tireoidiana prévia. A média do nível de TSH sérico entre os 100 indivíduos foi de 1.81 ± 1.08 uUI/mL. De acordo com o diagnóstico citopatológico da PAAF complementado pelos achados do bloco celular foram classificados como malignos 8% dos nódulos, 70% benignos, 11% suspeitos/ indeterminados, 8% insuficientes e 3% lesões foliculares. A média de TSH para os grupos maligno, benigno, suspeito/indeterminado, insuficiente e lesão folicular foi de, respectivamente, 2.48, 1.59, 2.21, 2.35 e 2.20 uUI/ml (p>0.05). Não houve diferença estatística significante entre os grupos diagnósticos avaliados, apesar de haver uma variação entre os níveis de TSH entre os grupos refletindo, provavelmente, o pequeno tamanho da amostra. / Thyroid nodules are common and currently the first choice of investigation in distinguishing benign from malignant disease is the cytological analysis of fine needle aspiration biopsy (FNAB). Previous studies have indicated that serum TSH levels might be associated with the likelihood of malignancy. The aim of this study was to evaluate whether serum TSH is a predictor of malignancy of thyroid nodules in patients undergoing FNAB. One hundred consecutive patients, who underwent FNAB as part of clinical investigation of thyroid nodule in a multidisciplinary setting tertiary hospital, underwent ultrasonography followed by FNAB, cytology and cell block analysis. Independent-Samples Kruskal-Wallis test was used to compare the groups. The study population comprised of 89 female and 11 male patients. The mean age was 54.1 ± 14.2 years. 26% had previous thyroid disease. Mean TSH levels was 1.81 ± 1.08 uUI/mL and the mean nodule size was 2.53 ± 1.36cm. Final cytology/cell block diagnosis classified 8% as malignant, 70% as benign, 11% suspicious/indeterminate, 8% insufficient and 3% follicular lesion. The mean TSH values for malignant, benign, suspect, insufficient and follicular lesion group were as follows: 2.48, 1.59, 2.21, 2.35 and 2.20 uUI/ml, respectively. No statistical significance was detected between TSH levels and final cytology/cell block diagnosis, possibly reflecting the small sample size (P>0.05). We observed a variation between TSH levels among the groups covered in this study, but there was no statistically significant difference among them.

In this study, meta-analysis of diagnostic tests, Summary Receiver Operating Characteristic (SROC) curve, bivariate random effects and Hierarchical Summary Receiver Operating Characteristic (HSROC) curve theories have been discussed and accuracy in literature of Fine Needle Aspiration (FNA) biopsy that is used in the diagnosis of masses in breast cancer (malignant or benign) has been analyzed. FNA Cytological (FNAC) examination in breast tumor is, easy, effective, effortless, and does not require special training for clinicians. Because of the uncertainty related to FNAC&lsquo / s accurate usage in publications, 25 FNAC studies have been gathered in the meta-analysis. In the plotting of the summary ROC curve, the logit difference and sums of the true positive rates and the false positive rates included in the meta-analysis&lsquo / s codes have been generated by SAS. The formula of the bivariate random effects model and hierarchical summary ROC curve is presented in context with the literature. Then bivariate random effects implementation with the new SAS PROC GLIMMIX is generated. Moreover, HSROC implementation is generated by SAS PROC HSROC NLMIXED. Curves are plotted with RevMan Version 5 (2008). It has been stated that the meta-analytic results of bivariate random effects are nearly identical to the results from the HSROC approach. The results achieved through both random effects meta-analytic methods prove that FNA Cytology is a diagnostic test with a high level of distinguish over breast tumor.

Nódulos de tireoide são achados clínicos comuns e, atualmente, o método diagnóstico de escolha para diferenciar lesões benignas de lesões malignas é a análise citopatológica dos nódulos através de punção aspirativa por agulha fina (PAAF). Estudos prévios já indicaram que os níveis séricos de TSH podem estar associados ao risco de malignidade nodular. O objetivo deste estudo foi avaliar se o TSH sérico é um preditor de malignidade em nódulos de tireoide em pacientes submetidos à PAAF. A amostra contemplou 100 indivíduos puncionados consecutivamente no Centro de Pronto Diagnóstico Ambulatorial, CPDA, HCPA e que apresentavam níveis de TSH dentro da normalidade. Todos os pacientes foram submetidos à PAAF da tireoide com controle ultrassonográfico e tiveram, posteriormente, a análise citopatológica da PAAF e a avaliação histopatológica do bloco celular. A análise estatística baseou-se em dados de frequências e testes não-paramétricos foram utilizados para correlacionar as variáveis. A população de estudo foi composta por 100 pacientes, sendo 89 mulheres e 11 homens. A média de idade foi de 54,1 ± 14,2 anos e o tamanho médio dos nódulos foi de 2.53 ± 1.36 centímetros. Vinte e seis % destes pacientes apresentavam algum tipo de doença tireoidiana prévia. A média do nível de TSH sérico entre os 100 indivíduos foi de 1.81 ± 1.08 uUI/mL. De acordo com o diagnóstico citopatológico da PAAF complementado pelos achados do bloco celular foram classificados como malignos 8% dos nódulos, 70% benignos, 11% suspeitos/ indeterminados, 8% insuficientes e 3% lesões foliculares. A média de TSH para os grupos maligno, benigno, suspeito/indeterminado, insuficiente e lesão folicular foi de, respectivamente, 2.48, 1.59, 2.21, 2.35 e 2.20 uUI/ml (p>0.05). Não houve diferença estatística significante entre os grupos diagnósticos avaliados, apesar de haver uma variação entre os níveis de TSH entre os grupos refletindo, provavelmente, o pequeno tamanho da amostra. / Thyroid nodules are common and currently the first choice of investigation in distinguishing benign from malignant disease is the cytological analysis of fine needle aspiration biopsy (FNAB). Previous studies have indicated that serum TSH levels might be associated with the likelihood of malignancy. The aim of this study was to evaluate whether serum TSH is a predictor of malignancy of thyroid nodules in patients undergoing FNAB. One hundred consecutive patients, who underwent FNAB as part of clinical investigation of thyroid nodule in a multidisciplinary setting tertiary hospital, underwent ultrasonography followed by FNAB, cytology and cell block analysis. Independent-Samples Kruskal-Wallis test was used to compare the groups. The study population comprised of 89 female and 11 male patients. The mean age was 54.1 ± 14.2 years. 26% had previous thyroid disease. Mean TSH levels was 1.81 ± 1.08 uUI/mL and the mean nodule size was 2.53 ± 1.36cm. Final cytology/cell block diagnosis classified 8% as malignant, 70% as benign, 11% suspicious/indeterminate, 8% insufficient and 3% follicular lesion. The mean TSH values for malignant, benign, suspect, insufficient and follicular lesion group were as follows: 2.48, 1.59, 2.21, 2.35 and 2.20 uUI/ml, respectively. No statistical significance was detected between TSH levels and final cytology/cell block diagnosis, possibly reflecting the small sample size (P>0.05). We observed a variation between TSH levels among the groups covered in this study, but there was no statistically significant difference among them.

Orientador: Wilter Ricardo Russiano Vicente / Banca: Marcelo Emílio Beletti / Banca: José Octávio Jacomini / Banca: Maria Rita Pacheco / Banca: Paulo Henrique Franceschini / Resumo: O objetivo deste estudo foi avaliar histologicamente as biópsias testiculares de cães obtidas por punção aspirativa por agulhas fina (PAAF) e "tru cut". Foram utilizados 40 cães, adultos, hígidos, distribuídos em 2 grupos: G1 - punção biópsia aspirativa; e G2 - biópsia com agulha "tru-cut". Cada grupo foi dividido em quatro subgrupos (Ga, Gb, Gc e Gd) com cinco animais cada, sendo estes orquiectomizados 3, 7, 14 e 62 dias após as biópsias PAAF ou "Tru-cut". O material colhido pela PAAF foi submetido à avaliação citológica, e o proveniente da biópsia "tru-cut" e orquiectomia submetidos à histopatologia. Foram avaliados os espermiogramas e mensuração de comprimento e largura do escroto e colhido o soro para pesquisa de anticorpo antiespermatozóides. Referente ao espermiograma e a mensuração do escroto não foram observados diferenças (p>0,05) significativas. A amostra direcionada para citologia e histologia obtida pelas duas técnicas foi considerada de quantidade suficiente para diagnóstico. Na histopatologia a PAAF apresentou menor área de lesão e reação inflamatória comparada a "tru cut", no entanto esta última apresentou maior quantidade de material, preservando a arquitetura dos túbulos seminíferos e interstício. Não foi observado diferença (p>0,05) na produção de anticorpos anti-espermatozóides, após as biopsias. Concluímos que apesar das biópsias fornecerem material em qualidade e quantidade adequadas, e da PAAF ter se mostrado menos traumática, a escolha da técnica a ser empregada dependerá da finalidade para o qual o material se destina. / Abstract: The aim of this study it was evaluate hystologicaly the testicular biopsies in dogs obtained by aspirative puncture by fine needle and "tru-cut". Forty males dogs, adults, healthies were used, distributed in 2 groups: G1 - Fine Needle aspiration; and G2- biopsy by "Tru-cut". Each group were shared in four groups (Ga, Gb, Gc e Gd) with 5 animals each, and all of then were orchiectomized after 3, 7, 14, 62 days after the biopsies by FNA and "tru-cut" being performed. The samples collected by FNA were submitted to cytology evaluate, and the sample from tru-cut biopsy and orchiectomy submitted to histopathology. The spermiograms were evaluated, the testicular length and with were measure, and the animal's blood were collected to the anti-sperm antibody quantification. About the spermogram and measurement of scrotal bag any significative difference was observed (p>0,05). The sample to cytology and histology obtained from two techniques showed be in quantity enough to diagnostic. In histopathology, the biopsy FNA showed smaller damage area and inflammatory reaction compared to tru-cut, however this one showed biggest quantity of material, preserving the seminiferous tubules architeture and interstitium. It was not observed significative difference at anti-sperm antibodies production. We concluded that althought the biopsies provide material in quantity and quality appropriate, and the PAAF showed less traumatic, the choose of the technique to be used will depend the purpose for which the material is intended. / Doutor

Nódulos de tireoide são achados clínicos comuns e, atualmente, o método diagnóstico de escolha para diferenciar lesões benignas de lesões malignas é a análise citopatológica dos nódulos através de punção aspirativa por agulha fina (PAAF). Estudos prévios já indicaram que os níveis séricos de TSH podem estar associados ao risco de malignidade nodular. O objetivo deste estudo foi avaliar se o TSH sérico é um preditor de malignidade em nódulos de tireoide em pacientes submetidos à PAAF. A amostra contemplou 100 indivíduos puncionados consecutivamente no Centro de Pronto Diagnóstico Ambulatorial, CPDA, HCPA e que apresentavam níveis de TSH dentro da normalidade. Todos os pacientes foram submetidos à PAAF da tireoide com controle ultrassonográfico e tiveram, posteriormente, a análise citopatológica da PAAF e a avaliação histopatológica do bloco celular. A análise estatística baseou-se em dados de frequências e testes não-paramétricos foram utilizados para correlacionar as variáveis. A população de estudo foi composta por 100 pacientes, sendo 89 mulheres e 11 homens. A média de idade foi de 54,1 ± 14,2 anos e o tamanho médio dos nódulos foi de 2.53 ± 1.36 centímetros. Vinte e seis % destes pacientes apresentavam algum tipo de doença tireoidiana prévia. A média do nível de TSH sérico entre os 100 indivíduos foi de 1.81 ± 1.08 uUI/mL. De acordo com o diagnóstico citopatológico da PAAF complementado pelos achados do bloco celular foram classificados como malignos 8% dos nódulos, 70% benignos, 11% suspeitos/ indeterminados, 8% insuficientes e 3% lesões foliculares. A média de TSH para os grupos maligno, benigno, suspeito/indeterminado, insuficiente e lesão folicular foi de, respectivamente, 2.48, 1.59, 2.21, 2.35 e 2.20 uUI/ml (p>0.05). Não houve diferença estatística significante entre os grupos diagnósticos avaliados, apesar de haver uma variação entre os níveis de TSH entre os grupos refletindo, provavelmente, o pequeno tamanho da amostra. / Thyroid nodules are common and currently the first choice of investigation in distinguishing benign from malignant disease is the cytological analysis of fine needle aspiration biopsy (FNAB). Previous studies have indicated that serum TSH levels might be associated with the likelihood of malignancy. The aim of this study was to evaluate whether serum TSH is a predictor of malignancy of thyroid nodules in patients undergoing FNAB. One hundred consecutive patients, who underwent FNAB as part of clinical investigation of thyroid nodule in a multidisciplinary setting tertiary hospital, underwent ultrasonography followed by FNAB, cytology and cell block analysis. Independent-Samples Kruskal-Wallis test was used to compare the groups. The study population comprised of 89 female and 11 male patients. The mean age was 54.1 ± 14.2 years. 26% had previous thyroid disease. Mean TSH levels was 1.81 ± 1.08 uUI/mL and the mean nodule size was 2.53 ± 1.36cm. Final cytology/cell block diagnosis classified 8% as malignant, 70% as benign, 11% suspicious/indeterminate, 8% insufficient and 3% follicular lesion. The mean TSH values for malignant, benign, suspect, insufficient and follicular lesion group were as follows: 2.48, 1.59, 2.21, 2.35 and 2.20 uUI/ml, respectively. No statistical significance was detected between TSH levels and final cytology/cell block diagnosis, possibly reflecting the small sample size (P>0.05). We observed a variation between TSH levels among the groups covered in this study, but there was no statistically significant difference among them.

Background: Reported results for thyroid nodule fine-needle aspiration (FNA) cytology mainly originate from tertiary centers. However, thyroid nodule FNA cytology is mainly performed in primary care settings for which the distribution of FNA Bethesda categories and their respective malignancy rates are largely unknown. Therefore, this study investigated FNA cytology malignancy rates of a large primary care setting to determine to what extent current evidence-based strategies for the malignancy risk stratification of thyroid nodules are applied and applicable in such primary care settings. Methods: In a primary care setting, 9460 FNAs of thyroid nodules were retrospectively analyzed from 8380 patients evaluated by one cytologist (I.R.) during a period of two years. The 8380 FNA cytologies were performed by 64 physicians in different private practices throughout Germany in primary care settings. Results: The cytopathologic results were classified according to theBethesda Systemas non-diagnostic in 19%, cyst/ cystic nodule in 21%, benign (including thyroiditis) in 48%, atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) in 6%, follicular neoplasms/suspicious for follicular neoplasm (FN/SFN) in 4%, suspicious for malignancy (SFM) in 1%, and malignant in 1%. The proportion of patients proceeding to surgery or with a follow-up of at least one year and the observed risks of malignancy were 22%/8% for AUS/FLUS, 69%/ 17% for FN/SFN, 78%/86% for SFM, and 71%/98% for malignant. For 112 cytologically suspicious and malignant FNAs, there were 102 true positives and 10 false positives, considering histology as gold standard. Conclusion: At variance with other data mostly originating from tertiary centers, these data demonstrate low percentages for malignant, SFM, FN/SFN, and AUS/FLUS, and high percentages for cysts/cystic nodules in this primary care setting in Germany. The risks of malignancy for malignant, SFM, AUS/FLUS, and FN/SFN FNA cytologies are according to Bethesda recommendations.:1 ABKÜRZUNGSVERZEICHNIS ............................................................................................................... 1 2 EINFÜHRUNG .......................................................................................................................................... 2 2.1 DAS ORGAN SCHILDDRÜSE ................................................................................................................................ 3 2.1.1 Anatomie der Schilddrüse ......................................................................................................................... 3 2.1.2 Funktion der Schilddrüse .......................................................................................................................... 3 2.2 SCHILDDRÜSENKNOTEN ..................................................................................................................................... 4 2.2.1 Epidemiologie der Schilddrüsenknoten .............................................................................................. 4 2.2.2 Ätiologie der Schilddrüsenknoten ......................................................................................................... 4 2.2.3 Jodversorgung in Deutschland ................................................................................................................ 5 2.2.4 Symptomatik der Schilddrüsenknoten ................................................................................................ 5 2.2.5 Diagnostik von Schilddrüsenknoten ..................................................................................................... 6 2.2.6 Die Feinnadelaspirationszytologie (FNA) ......................................................................................... 9 2.2.7 Therapeutisches Management ............................................................................................................ 11 2.3 DIE ABLEITUNG DER RATIONALE .................................................................................................................. 13 3 PUBLIKATIONSMANUSKRIPT ........................................................................................................ 14 4 ZUSAMMENFASSUNG ......................................................................................................................... 22 4.1 SCHLUSSFOLGERUNG ....................................................................................................................................... 26 5 LITERATURVERZEICHNIS ................................................................................................................ 28 6 ANLAGEN ............................................................................................................................................... 33 6.1 TABELLE 1: MALIGNITÄTSRISIKO NACH SONOGRAPHISCHEM ERSCHEINUNGSBILD UND FNA INDIKATION FÜR SCHILDDRÜSENKNOTEN (36) ........................................................................................................... 33 6.2 TABELLE 2: DAS BETHESDA SYSTEM FOR REPORTING THYROID CYTHOPATHOLOGY. DIAGNOSTISCHE KATEGORIEN UND MALIGNITÄTSRISIKEN (36) ........................................................................................................... 34 6.3 ABBILDUNG 1: ALGORITHMUS FÜR PATIENTEN MIT SCHILDDRÜSENKNOTEN NACH DER AMERICAN THYROID ASSOCIATION (36) .......................................................................................................................................... 35 6.4 DARSTELLUNG DES EIGENEN BEITRAGS AN DER PUBLIKATION ............................................................... 36 6.5 ERKLÄRUNG ÜBER DIE EIGENSTÄNDIGE ABFASSUNG DER ARBEIT .......................................................... 54 6.6 LEBENSLAUF ..................................................................................................................................................... 55 6.7 VERZEICHNIS WISSENSCHAFTLICHER VERÖFFENTLICHUNGEN ................................................................ 56 6.8 DANKSAGUNG ................................................................................................................................................... 57

Introduction: Effusion cytology can be performed for the purpose of diagnosis, treatment, and prognosis of malignant disease. A common analysis of effusion cytology samples is the May Grunwald Giemsa stain.    Aim: The aim of the study was to compare May Grunwald Giemsa stain and May Grunwald Giemsa Quick Stain in order to determine the best quality stain and suggest ways to improve the current staining protocol.     Materials and Methods: The methods used in this study are the routine laboratory’s standard procedures for  May-Grunwald Giemsa stain and May-Grunwald Giemsa Quick Stain but with adapted washing steps that investigates the effect of tap water, distilled water, and phosphate buffer on stain quality. Two pleural effusion samples were stained in the initial experiment and two pleural effusions and one ascites sample in the second experiment.    Results and Conclusion: All samples gave a greater score when stained with May-Grunwald Giemsa Quick Stain compared to traditional May-Grunwald Giemsa stain. For the traditional May-Grunwald Giemsa, the use of any of the three phosphate buffers scores higher than the routine washing where tap water is used. In conclusion, it would be of benefit to further investigate and implement phosphate buffer in traditional staining or proceed with the May-Grunwald Quick Stain for all pleural and ascites effusions.

Hinsichtlich einer effizienten Nachsorge von Melanompatienten existieren entsprechende Empfehlungen, aber auch widersprüchliche Stellungnahmen hinsichtlich Intervalllänge und Umfang der Nachsorge. Das Melanom ist einer der malignen Tumoren mit den am schnellsten steigenden Inzidenzraten, was auch eine Steigerung der Mortalität bedingt. In der vorliegenden Arbeit werden neue diagnostische Strategien geprüft und in ein vorbestehendes Melanomnachsorgeschema aufgenommen, um Patientenbetreuung, die frühe Entdeckung von Metastasen, aber auch die Raten an rezidivfreiem - und Gesamtüberleben zu verbessern. In einer großen prospektiven Studie von 4 Jahren Dauer konnte der Ultraschall von Lymphknoten, Weichteilgewebe und in transit Strecken eher als die rein klinische Untersuchung Metastasen entdecken und führte auf diese Weise zu einer Verbesserung des rezidivfreien- und des Gesamtüberlebens. Die Feinnadelaspirationszytologie (FNAC) wurde in einer weltweit, zahlenmäßig führenden Studie durchgeführt um die verdächtigten Läsionen tatsächlich zu diagnostizieren. Dies geschah hierbei nahezu nicht-invasiv. Hohe Zahlen an Sensitivität und Spezifität dieser Methode konnten erreicht werden und eine Diagnose konnte auch in sehr kleinen Läsionen oder solchen in einer schwierigen Position etabliert werden. Bei letzteren Läsionen erwies sich auch die Hinzunahme einer ultraschallgesteuerten Drahtmarkierung als nützliches Procedere. Auf diese Weise konnte die Exzision dieser Läsionen in komplizierter Lage vereinfacht werden. Eine weitere Studie untersuchte die begleitende Anwendung der Untersuchung einer seriellen reverse Transskriptase Polymerasekettenreaktion (RT-PCR) zum Nachweis von Tyrosinase aus peripherem Blut von Hochrisikomelanompatienten. Patienten, die im Blut mindestens einmal positiv getestet wurden, zeigten ein signifikant höheres Risiko, krankheitsspezifisch am Melanom zu versterben, als Patienten, die stets ein negatives Resultat aufwiesen. Die Tyrosinase RT-PCR Untersuchungen konnten auch an geringen Mengen Material wie Feinnadelaspiraten oder dem Feinnadelpunktaten des Sentinel Node erfolgreich durchgeführt werden. Alle aufgezeigten Methoden erwiesen sich als effektiv und wurden deswegen in das bestehende Nachsorgeprogramm der Melanompatienten an der Charité, Berlin aufgenommen. / There exist recommendations but also controversies about the necessity and effectiveness of a distinctive melanoma follow-up programme. Melanoma is one of the fastest increasing malignant tumours with increasing rates of incidence and mortality. In this work new strategies are implemented in a pre-existing melanoma follow-up schedule in order to ameliorate the care for patients, the detection of metastases and the relapse-free and overall survival rates. In a large prospective study taking four years the ultrasound of lymph nodes, soft tissues and in transit distances was shown to earlier detect recurrences than the clinical examination thus significantly enhancing recurrence-free and overall survival. Fine needle aspiration cytology (FNAC) has been performed in a large, worldwide leading study to verify the suspected lesions in a nearly non-invasive way. High percentages in sensitivity and specificity could be achieved also in small lesions or lesions in an unfavourable localization. The latter lesions have been shown to be better detectable by a marking procedure. An anchor wire has been sonographically placed within such a lesion to improve the successful excision. A further study examined the value of serial RT-PCR testing from peripheral blood in melanoma patients. Patients, who have been tested at least once positive, had a higher risk ratio to die disease-specifically from melanoma. This result has been highly significant. RT-PCR examinations could also be applied in small amounts of material such as fine needle aspirations or material of FNA C of the sentinel node. All modalities could be proven to be effective and therefore are included in the melanoma follow-up programme of the Charité, Humboldt University of Berlin.